Manhattan Scientifics Issues Follow up Report to Shareholders -"Pushing the Limits of Cancer Detection"
October 02 2014 - 8:28AM
Business Wire
Three months ago Manhattan Scientifics (OTCQB: MHTX) announced
the delivery of its 1st breakthrough cancer measurement instrument
to M.D. Anderson Cancer Center in Houston.
The Company's technology uses iron oxide nanoparticles and a
technique it calls Magnetic Relaxometry to locate and measure
cancers with a sensitivity that would provide a diagnosis years
before other known methods. It is generally believed that very
early detection of cancers may well lead to their early elimination
prior to metastasis and growth.
http://www.cancer.org/treatment/understandingyourdiagnosis/advancedcancer/advanced-cancer-what-is-metastatic.
Last January the company executed an agreement to collaborate
with M.D. Anderson to advance, demonstrate and validate its
breakthrough technology which was developed by Edward R. Flynn,
PhD.
Dr. Flynn is the founder and chief scientist of the company’s
subsidiary, Senior Scientific LLC whose research was funded by the
NIH over an 8 year period. Thereafter Manhattan Scientific
undertook the commercialization, management and financing to take
the science from "bench to bedside". The Company has recently
engaged special FDA consultants in order to accelerate regulatory
approval.
Sara McKenzie, FDA specialist said, "PharmaDirections is a
professional consulting firm that has ushered some 22
pharmaceutical and medical device companies, large and small,
through the labyrinth of the FDA. We have been retained to guide
your project through the regulatory process and are optimistic,
with high expectations, to be successful within a reasonable
timeframe. "
Management believes its technology will emerge as the next
important evolutionary step in cancer diagnostics; the next step
beyond X-ray, sonography, MRI, CT, and PET scanning.
About Manhattan Scientifics
Manhattan Scientifics Inc. (www.mhtx.com) is located in
New Mexico, New York and Montreal. It is focused on technology
transfer and commercialization of transformative technologies in
the nano medicine space. The company is presently developing
commercial medical prosthetics applications for its ultra-fine
grain metals and plans to commercialize the cancer research work
and nano medical applications developed by Senior Scientific LLC, a
unit of the Company.
Forward-looking statement
This press release contains forward-looking statements, which
are subject to a number of risks, assumptions and uncertainties
that could cause the Company's actual results to differ materially
from those projected in such forward-looking statements. Management
at Manhattan Scientifics believes that purchase of its shares
should be considered to be at the high end of the risk spectrum.
Forward-looking statements speak only as of the date made and are
not guarantees of future performance. We undertake no obligation to
publicly update or revise any forward-looking statements.
Manhattan Scientifics, Inc. PR & IRMarvin Maslow,
917-923-3300marvin@mhtx.comorCorporate Advisory/PRFastnet
Advisors:Anthony Furey,
631-665-1234mtfurey@fastnetadvisors.comorHawk Associates:Frank
Hawkins, 305-451-1888f.hawkins@hawkassociates.comorEuropean
Contact:Herbert Strauss, +43-316-296-316herbert "at" eu-ir.com
Manhattan Scientifics (PK) (USOTC:MHTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Manhattan Scientifics (PK) (USOTC:MHTX)
Historical Stock Chart
From Apr 2023 to Apr 2024